Clinical validation of a serum protein biomarker signature for the early diagnosis of pancreatic cancer.

Project Information

IMMPACT

Grant agreement ID: 672454

DOI 10.3030/672454

Project closed

EC signature date 15 July 2015

Start date 1 June 2015

End date 31 May 2018

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 4 244 969,25

EU contribution € 4 244 969,00

Coordinated by

IMMUNOVIA AB
Sweden

Deliverables

Other (1)

Simplified user interface

Documents, reports (5)

Interim prospective validation report

An interim report will be generated after 18 months into the study to make any necessary adjustments to the study and present the first validation results. This interim report will conclude the requested support from SME-instrument, though the study will continue for yet another 18 months to finalize the study.

Retrospective clinical study report OHSU Study

Retrospective clinical study report OHSU Study retrospective clinical investigation nr 2

Retrospective clinical study report Herlev Study

Retrospective clinical study report Herlev Study retrospective clinical investigation nr 1

Retrospective clinical study report OXFORD Study

Retrospective clinical study report OXFORD Study (retrospective clinical investigation nr 4)

Retrospective clinical study report PANCAN Study

Retrospective clinical study report PANCAN Study (retrospective clinical investigation nr 3)

Websites, patent fillings, videos etc. (1)

Project website